Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 4/20 | 0.40 |
| ▸ | AKR1C2 | P52895 | 4/20 | 0.40 |
| ▸ | AKR1C1 | Q04828 | 3/20 | 0.40 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.40 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 7/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.37 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.37 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1464590 | 0.83 | LMNA (0.39) | HDAC1LMNACA12CA1CA2 | |
| SCHEMBL15897520 | 0.83 | AKR1C3 (0.41) | HDAC1AKR1C3AKR1C2AKR1C1AKR1B10 | |
| SCHEMBL5676272 | 0.82 | LMNA (0.51) | HDAC1CYP3A4LMNAMEN1KMT2A | |
| SCHEMBL12827123 | 0.82 | LMNA (0.38) | HDAC1LMNAF10MEN1KMT2A | |
| SCHEMBL5360898 | 0.81 | AKR1C3 (0.38) | AKR1C3AKR1C2AKR1C1AKR1B10AKR1C4 | |
| SCHEMBL24821862 | 0.81 | ALOX5 (0.34) | AKR1C3AKR1C2AKR1C1AKR1B10AKR1C4 | |
| SCHEMBL26088245 | 0.81 | LMNA (0.38) | LMNAF10MEN1KMT2AL3MBTL1 | |
| SCHEMBL1464752 | 0.80 | ALDH1A1 (0.45) | LMNACA12CA1CA2CA7 | |
| SCHEMBL20703426 | 0.79 | OPRM1 (0.50) | — | |
| SCHEMBL19753115 | 0.79 | LMNA (0.51) | HDAC1CYP3A4LMNACA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735426-B2 | Vanilloid receptor ligands, pharmaceutical compositions containing them, process for making them and use thereof for treating pain and other conditions | GRUENENTHAL GMBH (DE) | 2014-05-27 | — | — | US | disclosed |
| US-8642657-B2 | 4-(methyl sulfonyl amino) phenyl analogues as vanilloid antagonist showing excellent analgesic activity and the pharmaceutical compositions comprising the same | GRUENENTHAL GMBH (DE) | 2014-02-04 | — | — | US | disclosed |
| US-8642657-B2 | 4-(methyl sulfonyl amino) phenyl analogues as vanilloid antagonist showing excellent analgesic activity and the pharmaceutical compositions comprising the same | GRUENENTHAL GMBH (DE) | 2014-02-04 | — | — | US | disclosed |
| US-8642657-B2 | 4-(methyl sulfonyl amino) phenyl analogues as vanilloid antagonist showing excellent analgesic activity and the pharmaceutical compositions comprising the same | GRUENENTHAL GMBH (DE) | 2014-02-04 | — | — | US | disclosed |
| CN-100537528-C | 4-(methyl sulfonyl amino) phenyl analogues as vanilloid antagonist showing excellent analgesic activity and the pharmaceutical compositions comprising the same | GRUENENTHAL GMBH (DE) | 2009-09-09 | — | — | CN | disclosed |
| US-20080275044-A1 | Vanilloid receptor ligands, pharmaceutical compositions containing them, process for making them and use thereof for treating pain and other conditions | GRUENENTHAL GMBH (DE) | 2008-11-06 | — | — | US | disclosed |
| EP-1658265-A4 | 4-(METHYL SULFONYL AMINO) PHENYL ANALOGUES AS VANILLOID ANTAGONIST SHOWING EXCELLENT ANALGESIC ACTIVITY AND THE PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | GRUENENTHAL GMBH (DE) | 2006-11-29 | — | — | EP | disclosed |
| US-20060258884-A1 | 4-(Methyl sulfonyl amino) phenyl analogues as vanilloid antagonist showing excellent analgesic activity and the pharmaceutical compositions comprising the same | GRUENENTHAL GMBH (DE) | 2006-11-16 | — | — | US | disclosed |
| CN-1852891-A | 4- (methylsulfonylamino) phenyl analogues as vanilloid antagonists with high analgesic activity and pharmaceutical compositions containing them | GRUENENTHAL GMBH (DE) | 2006-10-25 | — | — | CN | disclosed |
| EP-1658265-A1 | 4-(METHYL SULFONYL AMINO) PHENYL ANALOGUES AS VANILLOID ANTAGONIST SHOWING EXCELLENT ANALGESIC ACTIVITY AND THE PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | Grünenthal GmbH (DE) | 2006-05-24 | — | — | EP | disclosed |
| WO-2005003084-A1 | 4-(METHYL SULFONYL AMINO) PHENYL ANALOGUES AS VANILLOID ANTAGONIST SHOWING EXCELLENT ANALGESIC ACTIVITY AND THE PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | GRUNENTHAL GMBH (DE) | 2005-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258884-A1 | 4-(Methyl sulfonyl amino) phenyl analogues as vanilloid antagonist showing excellent analgesic activity and the pharmaceutical compositions comprising the same | TRPV1, TRPA1, GPR68 | HDAC1 3180/4885HDAC6 2707/4885AKR1C3 2411/4885 |
| US-20080275044-A1 | Vanilloid receptor ligands, pharmaceutical compositions containing them, process for making them and use thereof for treating pain and other conditions | TRPV1, TRPV2, TRPV3 | HDAC1 2943/4885HDAC6 1168/4885AKR1C3 1474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.